Literature DB >> 9683832

Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma.

M Ikeguchi1, M Ikeda, S Tatebe, M Maeta, N Kaibara.   

Abstract

We investigated the clinicopathological significance of dendritic cell infiltration (DCsI) in esophageal squamous cell carcinoma and in regional lymph nodes of 88 patients. The expression of mutated p53 protein and the degree of positive cancer cells of proliferating cell nuclear antigen (PCNA labeling index) in tumors were analyzed as biological markers. These factors were compared with the degree of DCsI in tumors and in lymph nodes. The number of dendritic cells (DCs) were counted and scored as per mm2 in each case. The degree of DCsI of tumors with expression of p53 (19/mm2, n=50) was significantly lower than that of DCsI in 38 tumors without expression of p53 (27/mm2, P=0.0411). However, no significant correlation was detected between the PCNA labeling index and the degree of DCsI in 88 primary tumors (P=0.1273). The degree of DCsI in 53 metastatic lymph nodes (30/mm2) was significantly lower than that of DCsI in 264 cancer-free regional lymph nodes (48/mm2, P=0. 02). Although the degree of DCsI in tumors was not an independent prognostic factor for the 78 surviving patients (P=0.2647), the 3-year survival rate of patients in stage III and IV who underwent curative operation and who had tumors with high DCsI (>9/mm2, n=16, 72%) was significantly higher than that of the 24 patients who had tumors with low DCsI (< or = 9/mm2, 21%, P=0.008). These findings indicate that DCs infiltrated in and around the esophageal cancer may play a defensive role of the hosts against the tumors. This immune defense of the hosts might be an important prognostic factor for patients with advanced esophageal cancer. However, cancer cells which express a mutated p53 protein might regulate the function or activity of DCs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683832     DOI: 10.3892/or.5.5.1185

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

Review 1.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

Review 2.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

3.  Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer.

Authors:  K Günther; T Radkow; M A Reymond; R Pflüger; A Dimmler; W Hohenberger; T Papadopoulos
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571

4.  CD1A-positive cells and HSP60 (HSPD1) levels in keratoacanthoma and squamous cell carcinoma.

Authors:  Daniela Cabibi; Everly Conway de Macario; Sabrina Ingrao; Rossana Porcasi; Francesco Zucco; Alberto J L Macario; Francesco Cappello; Francesca Rappa
Journal:  Cell Stress Chaperones       Date:  2015-10-06       Impact factor: 3.667

Review 5.  Immunologic function of dendritic cells in esophageal cancer.

Authors:  Wenfeng Yang; Jinming Yu
Journal:  Dig Dis Sci       Date:  2007-12-13       Impact factor: 3.199

6.  Integrated analysis of ceRNA network and tumor-infiltrating immune cells in esophageal cancer.

Authors:  Yuhua Chen; Hao Zhou; Zhendong Wang; Zhanghao Huang; Jinjie Wang; Miaosen Zheng; Xuejun Ni; Lei Liu
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

Review 7.  Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Authors:  Meng-Ying Cui; Xing Yi; Zhen-Zhen Cao; Dan-Xia Zhu; Jun Wu
Journal:  J Oncol       Date:  2022-09-05       Impact factor: 4.501

8.  Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities.

Authors:  Ryan J King; Fang Qiu; Fang Yu; Pankaj K Singh
Journal:  Front Cell Dev Biol       Date:  2021-07-08

9.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

Review 10.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Erika Vacchelli; Ilio Vitale; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fučíková; Isabelle Cremer; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.